

# Chronic heart failure in adults: management

Clinical guideline

Published: 25 August 2010

[nice.org.uk/guidance/cg108](https://www.nice.org.uk/guidance/cg108)

## Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

## Contents

Introduction .....	5
Patient-centred care .....	8
Key priorities for implementation .....	9
1 Guidance .....	12
1.1 Diagnosing heart failure .....	12
1.2 Treating heart failure .....	15
1.3 Rehabilitation.....	23
1.4 Monitoring.....	24
1.5 Referral and approach to care .....	25
2 Notes on the scope of the guidance .....	30
3 Implementation .....	31
4 Research recommendations .....	32
4.1 Beta-blockers and angiotensin-converting enzyme inhibitors for heart failure with preserved left ventricular ejection fraction .....	32
4.2 Home telemonitoring, natriuretic peptide-guided therapy and formal follow-up by a heart failure team .....	32
4.3 The role of natriuretic peptides in the management and prognosis of heart failure.....	33
4.4 Aldosterone antagonists and angiotensin II receptor antagonists in heart failure .....	33
4.5 Hydralazine in combination with nitrate for heart failure with preserved left ventricular ejection fraction .....	34
5 Other versions of this guideline.....	36
5.1 Full guideline.....	36
5.2 Information for the public .....	36
6 Related NICE guidance.....	37
7 Updating the guideline .....	38
Appendix A: The Guideline Development Group and NICE project team for the 2010 partial update .....	39
Guideline Development Group .....	39

NICE project team ..... 40

The Guideline Development Group for the 2003 guideline (with 2003 affiliations) ..... 41

Appendix B: The Guideline Review Panel for the 2010 partial update .....43

    The Guideline Review Panel for the 2003 guideline (with 2003 affiliations) ..... 43

Appendix C: The algorithms.....45

Appendix D: Practical notes.....46

About this guideline .....47

This guideline replaces CG5.

This guideline is the basis of QS9.

## Introduction

This guidance updates and replaces 'Chronic heart failure' (NICE clinical guideline 5 (2003)).

Heart failure is a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart as a pump is impaired. It is caused by structural or functional abnormalities of the heart. Some patients have heart failure due to left ventricular systolic dysfunction (LVSD) which is associated with a reduced left ventricular ejection fraction. Others have heart failure with a preserved ejection fraction (HFPEF). Most of the evidence on treatment is for heart failure due to LVSD. The most common cause of heart failure in the UK is coronary artery disease, and many patients have had a myocardial infarction in the past<sup>[1]</sup>.

Around 900,000 people in the UK have heart failure. Almost as many have damaged hearts but, as yet, no symptoms of heart failure<sup>[2]</sup>. Both the incidence and prevalence of heart failure increase steeply with age, with the average age at first diagnosis being 76 years<sup>[3]</sup>. The prevalence of heart failure is expected to rise in future as a result of an ageing population, improved survival of people with ischaemic heart disease and more effective treatments for heart failure<sup>[4]</sup>.

Heart failure has a poor prognosis: 30–40% of patients diagnosed with heart failure die within a year – but thereafter the mortality is less than 10% per year<sup>[5][6]</sup>. There is evidence of a trend of improved prognosis in the past 10 years. The 6-month mortality rate decreased from 26% in 1995 to 14% in 2005<sup>[7]</sup>.

Patients on GP heart failure registers, representing prevalent cases of heart failure, have a 5-year survival rate of 58% compared with 93% in the age- and sex-matched general population<sup>[8]</sup>. On average, a GP will look after 30 patients with heart failure, and suspect a new diagnosis of heart failure in perhaps ten patients annually<sup>[9]</sup>. Heart failure accounts for a total of 1 million inpatient bed-days – 2% of all NHS inpatient bed-days – and 5% of all emergency medical admissions to hospital. Hospital admissions because of heart failure are projected to rise by 50% over the next 25 years – largely as a result of the ageing population<sup>[10][11]</sup>. This is despite a progressive decline of the age-adjusted hospitalisation rate at 1–1.5% per annum since 1992/93<sup>[12]</sup>.

For both patients and their carers heart failure can be a financial burden and have adverse effects on their quality of life.

Since we published 'Chronic heart failure: management of chronic heart failure in adults in primary and secondary care' (NICE clinical guideline 5) in 2003, new high-quality evidence from randomised controlled trials in diagnosis, treatment, rehabilitation and monitoring has been published. This guideline is an update of NICE clinical guideline 5 and replaces it. New recommendations have been made in line with the new evidence.

The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients.

New and updated recommendations are included on diagnosis, pharmacological treatment, monitoring and rehabilitation.

Recommendations are marked as [2003], [2003, amended 2010], [2006], [2007], [2010] or [new 2010].

[2003] indicates that the evidence has not been updated and reviewed since 2003

[2003, amended 2010] indicates that the evidence has not been updated and reviewed since 2003 but a small amendment has been made to the recommendation

[2006] applies to guidance from 'Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias', [NICE technology appraisal 95](#), published in 2006

[2007] applies to two recommendations from 'MI: secondary prevention', [NICE clinical guideline 48](#) and guidance from 'Cardiac resynchronisation therapy for the treatment of heart failure', [NICE technology appraisal 120](#), both published in 2007

[2010] indicates that the evidence has been reviewed but no changes have been made to the recommendation

---

<sup>[1]</sup> Petersen S, Rayner M, Wolstenholme J (2002) Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation

<sup>[2]</sup> Petersen S, Rayner M, Wolstenholme J (2002) Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation

- [3] Cowie MR, Wood DA, Coats AJ et al.(1999) Incidence and aetiology of heart failure; a population-based study. *European Heart Journal* 20: 421–8
- [4] Owan TE, Hodge DO, Herges RM et al. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. *New England Journal of Medicine* 355: 251–9
- [5] Cowie MR, Wood DA, Coats AJ et al. (2000) Survival of patients with a new diagnosis of heart failure: a population based study. *Heart* 83: 505–10
- [6] Hobbs FD, Roalfe AK, Davis RC et al. (2007) Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). *European Heart Journal* 28: 1128–34
- [7] Mehta PA, Dubrey SW, McIntyre HF, Walker DM et al. (2009) Improving survival in the 6 months after diagnosis of heart failure in the past decade: population-based data from the UK. *Heart* 95: 1851–6
- [8] Hobbs FD, Roalfe AK, Davis RC et al. (2007) Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). *European Heart Journal* 28: 1128–34
- [9] Stewart S, Horowitz JD (2002) Home-based intervention in congestive heart failure: long-term implications on readmission and survival. *Circulation* 105: 2861–6
- [10] Stewart S, Horowitz JD (2002) Home-based intervention in congestive heart failure: long-term implications on readmission and survival. *Circulation* 105: 2861–6
- [11] Petersen S, Rayner M, Wolstenholme J (2002) Coronary heart disease statistics: heart failure supplement. London: British Heart Foundation
- [12] Mosterd A, Reitsma JB, Grobbee DE (2002) Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? *Heart* 87: 75–6

## Patient-centred care

This guideline offers best practice advice on the care of adults with chronic heart failure.

Treatment and care should take into account patients' needs and preferences. People with chronic heart failure should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If patients do not have the capacity to make decisions, healthcare professionals should follow the [Department of Health's advice on consent](#) and the [code of practice that accompanies the Mental Capacity Act](#). In Wales, healthcare professionals should follow [advice on consent from the Welsh Government](#).

Good communication between healthcare professionals and patients is essential. It should be supported by evidence-based written information tailored to the patient's needs. Treatment and care, and the information patients are given about it, should be culturally appropriate. It should also be accessible to people with additional needs such as physical, sensory or learning disabilities, and to people who do not speak or read English.

If the patient agrees, families and carers should have the opportunity to be involved in decisions about treatment and care.

Families and carers should also be given the information and support they need.



## Key priorities for implementation

The following recommendations have been identified as priorities for implementation.

### Diagnosis

- Refer patients with suspected heart failure and previous myocardial infarction (MI) urgently, to have transthoracic Doppler 2D echocardiography and specialist assessment within 2 weeks. [new 2010]
- Measure serum natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal pro-B-type natriuretic peptide [NTproBNP]) in patients with suspected heart failure without previous MI. [new 2010]
- Because very high levels of serum natriuretic peptides carry a poor prognosis, refer patients with suspected heart failure and a BNP level above 400 pg/ml (116 pmol/litre) or an NTproBNP level above 2000 pg/ml (236 pmol/litre) urgently, to have transthoracic Doppler 2D echocardiography and specialist assessment within 2 weeks. [new 2010]

### Treatment

- Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. [new 2010]
- Offer beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction, including:
  - older adults and
  - patients with:
    - ◇ peripheral vascular disease
    - ◇ erectile dysfunction
    - ◇ diabetes mellitus
    - ◇ interstitial pulmonary disease and
    - ◇ chronic obstructive pulmonary disease (COPD) without reversibility. [new 2010]

- Seek specialist advice and consider adding one of the following if a patient remains symptomatic despite optimal therapy with an ACE inhibitor and a beta-blocker:
  - an aldosterone antagonist licensed for heart failure (especially if the patient has moderate to severe heart failure [NYHA<sup>[13]</sup> class III–IV] or has had an MI within the past month) or
  - an angiotensin II receptor antagonist (ARB) licensed for heart failure<sup>[14]</sup> (especially if the patient has mild to moderate heart failure [NYHA class II–III]) or
  - hydralazine in combination with nitrate (especially if the patient is of African or Caribbean origin<sup>[15]</sup> and has moderate to severe heart failure [NYHA class III–IV]) [new 2010]

## Rehabilitation

- Offer a supervised group exercise-based rehabilitation programme designed for patients with heart failure.
  - Ensure the patient is stable and does not have a condition or device that would preclude an exercise-based rehabilitation programme<sup>[16]</sup>.
  - Include a psychological and educational component in the programme.
  - The programme may be incorporated within an existing cardiac rehabilitation programme. [new 2010]

## Monitoring

- All patients with chronic heart failure require monitoring. This monitoring should include:
  - a clinical assessment of functional capacity, fluid status, cardiac rhythm (minimum of examining the pulse), cognitive status and nutritional status
  - a review of medication, including need for changes and possible side effects
  - serum urea, electrolytes, creatinine and eGFR<sup>[17]</sup>. [2003, amended 2010]
- When a patient is admitted to hospital because of heart failure, seek advice on their management plan from a specialist in heart failure. [new 2010]

## Discharge planning

- Patients with heart failure should generally be discharged from hospital only when their clinical condition is stable and the management plan is optimised. Timing of discharge should take into account patient and carer wishes, and the level of care and support that can be provided in the community. [2003]

---

<sup>[13]</sup> The New York Heart Association classification of heart failure.

<sup>[14]</sup> Not all ARBs are licensed for use in heart failure in combination with ACE inhibitors.

<sup>[15]</sup> This does not include mixed race. For more information see the [full guideline](#)

<sup>[16]</sup> The conditions and devices that may preclude an exercise-based rehabilitation programme include: uncontrolled ventricular response to atrial fibrillation, uncontrolled hypertension, and high-energy pacing devices set to be activated at rates likely to be achieved during exercise.

<sup>[17]</sup> This is a minimum. Patients with comorbidities or co-prescribed medications will require further monitoring. Monitoring serum potassium is particularly important if a patient is taking digoxin or an aldosterone antagonist.

# 1 Guidance

The following guidance is based on the best available evidence. The [full guideline](#) gives details of the methods and the evidence used to develop the guidance.

## Heart failure due to left ventricular systolic dysfunction (LVSD)

This is caused by impaired left ventricular contraction, and is usually characterised by a reduced left ventricular ejection fraction.

## Heart failure with preserved ejection fraction (HFPEF)

This is usually associated with impaired left ventricular relaxation, rather than left ventricular contraction, and is characterised by a normal or preserved left ventricular ejection fraction.

## Specialist

Throughout this guideline, the term 'specialist' denotes a physician with subspecialty interest in heart failure (often a consultant cardiologist) who leads a specialist multidisciplinary heart failure team of professionals with appropriate competencies from primary and secondary care. The team will involve, where necessary, other services (such as rehabilitation, tertiary care and palliative care) in the care of individual patients.

Unless otherwise specified, within this guideline specialist assessment or management refers to assessment or management by this specialist multidisciplinary heart failure team. The team will decide who is the most appropriate team member to address a particular clinical problem.

## 1.1 *Diagnosing heart failure*

### 1.1.1 Symptoms, signs and investigations

1.1.1.1 Take a careful and detailed history, and perform a clinical examination and tests to confirm the presence of heart failure. [2010]

1.1.1.2 Refer patients with suspected heart failure and previous myocardial infarction (MI) urgently, to have transthoracic Doppler 2D echocardiography and specialist assessment within 2 weeks. [new 2010]

- 1.1.1.3 Measure serum natriuretic peptides (B-type natriuretic peptide [BNP] or N-terminal pro-B-type natriuretic peptide [NTproBNP]) in patients with suspected heart failure without previous MI. [new 2010]
- 1.1.1.4 Because very high levels of serum natriuretic peptides carry a poor prognosis, refer patients with suspected heart failure and a BNP level above 400 pg/ml (116 pmol/litre) or an NTproBNP level above 2000 pg/ml (236 pmol/litre) urgently, to have transthoracic Doppler 2D echocardiography and specialist assessment within 2 weeks. [new 2010]
- 1.1.1.5 Refer patients with suspected heart failure and a BNP level between 100 and 400 pg/ml (29–116 pmol/litre) or an NTproBNP level between 400 and 2000 pg/ml (47–236 pmol/litre) to have transthoracic Doppler 2D echocardiography and specialist assessment within 6 weeks. [new 2010]
- 1.1.1.6 Be aware that:
- obesity or treatment with diuretics, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin II receptor antagonists (ARBs) and aldosterone antagonists can reduce levels of serum natriuretic peptides
  - high levels of serum natriuretic peptides can have causes other than heart failure (for example, left ventricular hypertrophy, ischaemia, tachycardia, right ventricular overload, hypoxaemia [including pulmonary embolism], renal dysfunction [GFR 60 ml/minute], sepsis, chronic obstructive pulmonary disease [COPD], diabetes, age 70 years and cirrhosis of the liver). [new 2010]
- 1.1.1.7 Perform transthoracic Doppler 2D echocardiography to exclude important valve disease, assess the systolic (and diastolic) function of the (left) ventricle, and detect intracardiac shunts. [2003]
- 1.1.1.8 Transthoracic Doppler 2D echocardiography should be performed on high-resolution equipment, by experienced operators trained to the relevant professional standards. Need and demand for these studies should not compromise quality. [2003]
- 1.1.1.9 Ensure that those reporting echocardiography are experienced in doing so. [2003]

1.1.1.10 Consider alternative methods of imaging the heart (for example, radionuclide angiography, cardiac magnetic resonance imaging or transoesophageal Doppler 2D echocardiography) when a poor image is produced by transthoracic Doppler 2D echocardiography. [2003]

1.1.1.11 Consider a serum natriuretic peptide test (if not already performed) when heart failure is still suspected after transthoracic Doppler 2D echocardiography has shown a preserved left ventricular ejection fraction. [new 2010]

1.1.1.12 Be aware that:

- a serum BNP level less than 100 pg/ml (29 pmol/litre) or an NTproBNP level less than 400 pg/ml (47 pmol/litre) in an untreated patient makes a diagnosis of heart failure unlikely
- the level of serum natriuretic peptide does not differentiate between heart failure due to left ventricular systolic dysfunction and heart failure with preserved left ventricular ejection fraction. [new 2010]

1.1.1.13 Perform an ECG and consider the following tests to evaluate possible aggravating factors and/or alternative diagnoses:

- chest X-ray
- blood tests:
  - electrolytes, urea and creatinine
  - eGFR (estimated glomerular filtration rate)
  - thyroid function tests
  - liver function tests
  - fasting lipids
  - fasting glucose
  - full blood count
- urinalysis

- peak flow or spirometry. [2003, amended 2010]

1.1.1.14 Try to exclude other disorders that may present in a similar manner. [2003]

1.1.1.15 When a diagnosis of heart failure has been made, assess severity, aetiology, precipitating factors, type of cardiac dysfunction and correctable causes. [new 2010]

## 1.1.2 Review of existing diagnoses

1.1.2.1 The basis for historical diagnosis of heart failure should be reviewed, and only patients whose diagnosis is confirmed should be managed in accordance with this guideline. [2003]

1.1.2.2 If the diagnosis of heart failure is still suspected, but confirmation of the underlying cardiac abnormality has not occurred, then the patient should have appropriate further investigation. [2003]

## 1.2 *Treating heart failure*

### 1.2.1 Lifestyle

#### Exercise

See [section 1.3](#), 'Rehabilitation'.

#### Smoking

1.2.1.1 Patients should be strongly advised not to smoke. Referral to smoking cessation services should be considered. [2003]

#### Alcohol

1.2.1.2 Patients with alcohol-related heart failure should abstain from drinking alcohol. [2003]

1.2.1.3 Healthcare professionals should discuss alcohol consumption with the patient and tailor their advice appropriately to the clinical circumstances. [2003]

## Sexual activity

- 1.2.1.4 Healthcare professionals should be prepared to broach sensitive issues with patients, such as sexual activity, as these are unlikely to be raised by the patient. [2003]

## Vaccination

- 1.2.1.5 Patients with heart failure should be offered an annual vaccination against influenza. [2003]
- 1.2.1.6 Patients with heart failure should be offered vaccination against pneumococcal disease (only required once). [2003]

## Air travel

- 1.2.1.7 Air travel will be possible for the majority of patients with heart failure, depending on their clinical condition at the time of travel. [2003]

## Driving regulations

- 1.2.1.8 Large Goods Vehicle and Passenger Carrying Vehicle licence: physicians should be up to date with the latest Driver and Vehicle Licensing Agency guidelines. Check the [website](#) for regular updates [2003]

## 1.2.2 Pharmacological treatment of heart failure

### Medicines adherence

For more information refer to 'Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence', [NICE clinical guideline 76](#) (2009).

- 1.2.2.1 Dosing regimens should be kept as simple as possible, and the healthcare professional should ensure that the patient and carer are fully informed about their medication. [2003]

### Heart failure due to left ventricular systolic dysfunction



### *First-line treatment*

See also recommendations 1.2.2.5, 1.2.2.6, 1.2.2.7, 1.2.2.8 and 1.2.2.9 on the use of ACE inhibitors and beta-blockers for first-line treatment. See recommendations 1.2.2.14 and 1.2.2.15 for alternative first-line treatment for patients who are intolerant of ACE inhibitors. See recommendation 1.2.2.13 for alternative first-line treatment for patients who are intolerant of ACE inhibitors and ARBs.

- 1.2.2.2 Offer both angiotensin-converting enzyme (ACE) inhibitors and beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction. Use clinical judgement when deciding which drug to start first. [new 2010]

### *Second-line treatment*

See also recommendations 1.2.2.10, 1.2.2.11, 1.2.2.12 and 1.2.2.15 on second-line treatments.

- 1.2.2.3 Seek specialist advice before offering second-line treatment to patients with heart failure due to left ventricular systolic dysfunction. [new 2010]
- 1.2.2.4 Seek specialist advice and consider adding one of the following if a patient remains symptomatic despite optimal therapy with an ACE inhibitor and a beta-blocker:
- an aldosterone antagonist licensed for heart failure (especially if the patient has moderate to severe heart failure [NYHA<sup>[18]</sup> class III–IV] or has had an MI within the past month) or
  - an angiotensin II receptor antagonist (ARB) licensed for heart failure<sup>[19]</sup> (especially if the patient has mild to moderate heart failure [NYHA class II–III]) or
  - hydralazine in combination with nitrate (especially if the patient is of African or Caribbean origin<sup>[20]</sup> and has moderate to severe heart failure [NYHA class III–IV]) [new 2010]

### *ACE inhibitors (first-line treatment)*

See also recommendation 1.2.2.2.

1.2.2.5 Start ACE inhibitor therapy at a low dose and titrate upwards at short intervals (for example, every 2 weeks) until the optimal tolerated or target dose is achieved. [2010]

1.2.2.6 Measure serum urea, creatinine, electrolytes and eGFR at initiation of an ACE inhibitor and after each dose increment<sup>[21],[22]</sup>. [2010]

#### *Beta-blockers (first-line treatment)*

See also recommendation 1.2.2.2.

1.2.2.7 Offer beta-blockers licensed for heart failure to all patients with heart failure due to left ventricular systolic dysfunction, including:

- older adults and
- patients with:
  - peripheral vascular disease
  - erectile dysfunction
  - diabetes mellitus
  - interstitial pulmonary disease and
  - chronic obstructive pulmonary disease (COPD) without reversibility. [new 2010]

1.2.2.8 Introduce beta-blockers in a 'start low, go slow' manner, and assess heart rate, blood pressure, and clinical status after each titration. [2010]

1.2.2.9 Switch stable patients who are already taking a beta-blocker for a comorbidity (for example, angina or hypertension), and who develop heart failure due to left ventricular systolic dysfunction, to a beta-blocker licensed for heart failure. [new 2010]

#### *Aldosterone antagonists (second-line treatment)*

See also recommendations 1.2.2.3 and 1.2.2.4.

- 1.2.2.10 In patients with heart failure due to left ventricular systolic dysfunction who are taking aldosterone antagonists, closely monitor potassium and creatinine levels, and eGFR. Seek specialist advice if the patient develops hyperkalaemia or renal function deteriorates<sup>[22]</sup>. [new 2010]
- 1.2.2.11 For patients who have had an acute MI and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, treatment with an aldosterone antagonist licensed for post-MI treatment should be initiated within 3–14 days of the MI, preferably after ACE inhibitor therapy. (This recommendation is from [MI: secondary prevention](#), NICE clinical guideline 48.) [2007]
- 1.2.2.12 Patients who have recently had an acute MI and have clinical heart failure and left ventricular systolic dysfunction, but who are already being treated with an aldosterone antagonist for a concomitant condition (for example, chronic heart failure), should continue with the aldosterone antagonist or an alternative, licensed for early post-MI treatment. (This recommendation is from 'MI: secondary prevention', NICE clinical guideline 48.) [2007]

*Hydralazine in combination with nitrate (alternative first-line treatment)*

See recommendations 1.2.2.3 and 1.2.2.4 for the use of hydralazine in combination with nitrate as second-line treatment.

- 1.2.2.13 Seek specialist advice and consider hydralazine in combination with nitrate for patients with heart failure due to left ventricular systolic dysfunction who are intolerant of ACE inhibitors and ARBs. [new 2010]

*Angiotensin II receptor antagonists (second-line or alternative first-line treatment)*

See also recommendations 1.2.2.3 and 1.2.2.4 for the use of ARBs as second-line treatment.

- 1.2.2.14 Consider an ARB licensed for heart failure as an alternative to an ACE inhibitor for patients with heart failure due to left ventricular systolic dysfunction who have intolerable side effects with ACE inhibitors. [new 2010]

1.2.2.15 Monitor serum urea, electrolytes, creatinine and eGFR for signs of renal impairment or hyperkalaemia in patients with heart failure who are taking an ARB.<sup>[23],[22]</sup> [new 2010]

### *Digoxin*

1.2.2.16 Digoxin is recommended for:

- worsening or severe heart failure due to left ventricular systolic dysfunction despite first- and second-line treatment for heart failure<sup>[24]</sup>. [2003, amended 2010]

### **All types of heart failure**

#### *Diuretics*

1.2.2.17 Diuretics should be routinely used for the relief of congestive symptoms and fluid retention in patients with heart failure, and titrated (up and down) according to need following the initiation of subsequent heart failure therapies. [2003]

1.2.2.18 The diagnosis and treatment of heart failure with preserved ejection fraction should be made by a specialist, and other conditions that present in a similar way may need to be considered. Patients in whom this diagnosis has been made should usually be treated with a low to medium dose of loop diuretics (for example, less than 80 mg furosemide per day). Patients who do not respond to this treatment will require further specialist advice. [2003]

#### *Calcium channel blockers*

1.2.2.19 Amlodipine should be considered for the treatment of comorbid hypertension and/or angina in patients with heart failure, but verapamil, diltiazem or short-acting dihydropyridine agents should be avoided. [2003]

#### *Amiodarone*

1.2.2.20 The decision to prescribe amiodarone should be made in consultation with a specialist. [2003]

1.2.2.21 The need to continue the amiodarone prescription should be reviewed regularly. [2003]

1.2.2.22 Patients taking amiodarone should have a routine 6-monthly clinical review, including liver and thyroid function test, and including a review of side effects. [2003]

#### *Anticoagulants<sup>[24]</sup>*

1.2.2.23 In patients with heart failure in sinus rhythm, anticoagulation should be considered for those with a history of thromboembolism, left ventricular aneurysm, or intracardiac thrombus. [2003]

#### *Aspirin*

1.2.2.24 Aspirin (75–150 mg once daily) should be prescribed for patients with the combination of heart failure and atherosclerotic arterial disease (including coronary heart disease). [2003]

#### *Inotropic agents*

1.2.2.25 Intravenous inotropic agents (such as dobutamine, milrinone or enoximone) should only be considered for the short-term treatment of acute decompensation of chronic heart failure. This will require specialist advice. [2003]

#### *Heart failure due to valve disease*

1.2.2.26 Patients with heart failure due to valve disease should be referred for specialist assessment and advice regarding follow-up. [2003]

1.2.2.27 ACE inhibitor therapy should not be initiated in a patient with a clinical suspicion of haemodynamically significant valve disease, until the valve disease has been assessed by a specialist. [2003]

#### **General**

#### *Age*

1.2.2.28 The management of heart failure should be determined by clinical criteria, irrespective of the age of the patient. [2003]

1.2.2.29 Tolerance of drugs may be lower and side effects require closer and more frequent monitoring in older patients. [2003]

#### *Gender*

1.2.2.30 The principles of pharmacological management of heart failure should be the same for men and women. [2003]

1.2.2.31 In women of reproductive age who have heart failure, contraception and pregnancy should be discussed. If pregnancy is being considered or occurs, specialist advice should be sought. Subsequently, specialist care should be shared between the cardiologist and obstetrician. [2003]

1.2.2.32 The potential teratogenic effects of drugs should be considered. [2003]

#### *Comorbidities*

1.2.2.33 Manage comorbidities according to:

- 'Hypertension', NICE clinical guideline 34 (replaced by '[Hypertension](#)' [NICE clinical guideline 127])
- '[MI: secondary prevention](#)', NICE clinical guideline 48
- '[Type 2 diabetes](#)', NICE clinical guideline 87
- and other relevant NICE guidance.

This is particularly important in heart failure with preserved ejection fraction. [new 2010]

### **1.2.3 Invasive procedures**

#### *Coronary revascularisation*

- 1.2.3.1 Coronary revascularisation should not be routinely considered in patients with heart failure due to systolic left ventricular impairment, unless they have refractory angina. [2003]

#### *Cardiac transplantation*

- 1.2.3.2 Specialist referral for transplantation should be considered in patients with severe refractory symptoms or refractory cardiogenic shock. [2003]

#### *Cardiac resynchronisation therapy*

Refer to 'Cardiac resynchronisation therapy for the treatment of heart failure' (NICE technology appraisal guidance 120 [2007]). Please refer to the NICE website for updates on the review status of this appraisal.

#### *Implantable cardioverter defibrillators*

Refer to 'Implantable cardioverter defibrillators for arrhythmias' (NICE technology appraisal guidance 95 [2006]). Please refer to the NICE website for updates on the review status of this appraisal.

### **1.3 Rehabilitation**

- 1.3.1.1 Offer a supervised group exercise-based rehabilitation programme designed for patients with heart failure.
- Ensure the patient is stable and does not have a condition or device that would preclude an exercise-based rehabilitation programme<sup>[25]</sup>.
  - Include a psychological and educational component in the programme.
  - The programme may be incorporated within an existing cardiac rehabilitation programme. [new 2010]

## 1.4 *Monitoring*

### 1.4.1 Clinical review

1.4.1.1 All patients with chronic heart failure require monitoring. This monitoring should include:

- a clinical assessment of functional capacity, fluid status, cardiac rhythm (minimum of examining the pulse), cognitive status and nutritional status
- a review of medication, including need for changes and possible side effects
- serum urea, electrolytes, creatinine and eGFR<sup>[26]</sup>. [2003, amended 2010]

1.4.1.2 More detailed monitoring will be required if the patient has significant comorbidity or if their condition has deteriorated since the previous review. [2003]

1.4.1.3 The frequency of monitoring should depend on the clinical status and stability of the patient. The monitoring interval should be short (days to 2 weeks) if the clinical condition or medication has changed, but is required at least 6-monthly for stable patients with proven heart failure. [2003]

1.4.1.4 Patients who wish to be involved in monitoring of their condition should be provided with sufficient education and support from their healthcare professional to do this, with clear guidelines as to what to do in the event of deterioration. [2003]

1.4.1.5 When a patient is admitted to hospital because of heart failure, seek advice on their management plan from a specialist in heart failure. [new 2010]

### 1.4.2 Serum digoxin

1.4.2.1 Routine monitoring of serum digoxin concentrations is not recommended. A digoxin concentration measured within 8–12 hours of the last dose may be useful to confirm a clinical impression of toxicity or non-adherence. [2003]

1.4.2.2 The serum digoxin concentration should be interpreted in the clinical context as toxicity may occur even when the concentration is within the 'therapeutic range'. [2003].



### **1.4.3 Serum natriuretic peptides**

- 1.4.3.1 Consider specialist monitoring of serum natriuretic peptides in some patients (for example, those in whom up titration is problematic or those who have been admitted to hospital). [new 2010]

## **1.5 Referral and approach to care**

### **1.5.1 Referral for more specialist advice**

- 1.5.1.1 Refer patients to the specialist multidisciplinary heart failure team for:
- the initial diagnosis of heart failure and
  - the management of:
    - severe heart failure (NYHA class IV)
    - heart failure that does not respond to treatment
    - heart failure that can no longer be managed effectively in the home setting. [new 2010]

### **1.5.2 Discharge planning**

- 1.5.2.1 Patients with heart failure should generally be discharged from hospital only when their clinical condition is stable and the management plan is optimised. Timing of discharge should take into account patient and carer wishes, and the level of care and support that can be provided in the community. [2003]
- 1.5.2.2 The primary care team, patient and carer must be aware of the management plan. [2003]
- 1.5.2.3 Clear instructions should be given as to how the patient/carers can access advice, particularly in the high-risk period immediately following discharge. [2003]

### **1.5.3 Multidisciplinary team approach to heart failure management**

- 1.5.3.1 Heart failure care should be delivered by a multidisciplinary team with an integrated approach across the healthcare community. [2003]

## 1.5.4 Non-NHS agencies

- 1.5.4.1 Standard one of the 'National service framework for older people' states: 'social care services will not use age in their eligibility criteria or policies to restrict access to available services'. This applies to patients with heart failure. (See [Department of Health](#)) [2003]
- 1.5.4.2 Management plans for patients with heart failure should be discussed with non-NHS agencies where they are involved in or responsible for the care of a person with heart failure. [2003]
- 1.5.4.3 The principles of pharmacological management for a patient cared for in a non-NHS institution should be similar to those for any other patient with heart failure. [2003]
- 1.5.4.4 The education needs of non-NHS agency carers should be considered. [2003]

## 1.5.5 Communication

- 1.5.5.1 Good communication between healthcare professionals and patients and carers is essential for the best management of heart failure. [2003]
- 1.5.5.2 Guidelines for good communication:
- Listen to patients and respect their views and beliefs.
  - Give patients the information they ask for or need about their condition, its treatment and prognosis, in a way they can understand including information about any serious side effects of drugs to be prescribed.
  - Provide the most important information first.
  - Explain how each item will affect patients personally.
  - Present information in separate categories.
  - Make advice specific, detailed and concrete.
  - Use words the patients will understand; confirm understanding by questions; define unfamiliar words; write down key words; draw diagrams and keep a copy in the medical notes.

- Repeat the information using the same words each time.
- Prepare material, written or taped, to back up handwritten notes.
- Share information with patients' partners, close relatives or carers if they ask you to do so. When patients cannot indicate their consent for such sharing of information, it is advisable to share the information that those close to the patient need or want to know, except where you have reason to believe that the patient would object if able to do so. [2003]

1.5.5.3 The content, style and timing of information provision should be tailored to the needs of the individual patient. [2003]

1.5.5.4 Healthcare professionals should assess cognitive ability when sharing information. [2003]

1.5.5.5 Carers and relatives of patients who are cognitively impaired should be made aware of treatment regimes for the patients they care for and be encouraged to identify any need for clinical support. [2003]

1.5.5.6 Management of heart failure should be seen as a shared responsibility between patient and healthcare professional. [2003]

1.5.5.7 Unless specifically excluded by the patient, carers and relatives should be involved in the management of the patient, particularly where the patient cannot look after him- or herself. [2003]

## 1.5.6 Prognosis

1.5.6.1 Prognosis should be discussed with patients and carers in a sensitive, open and honest manner. [2003]

## 1.5.7 Support groups

1.5.7.1 Healthcare professionals should be aware of local cardiac support networks and provide this information to patients and carers. [2003]

## 1.5.8 Anxiety and depression

- 1.5.8.1 The diagnosis of depression should be considered in all patients with heart failure. [2003]
- 1.5.8.2 Where depression is likely to have been precipitated by heart failure symptoms then reassessment of psychological status should be undertaken once the physical condition has stabilised following treatment for heart failure. If the symptoms have improved no further specific treatment for depression is required. [2003]
- 1.5.8.3 Where it is apparent that depression is co-existing with heart failure, then the patient should be treated for depression in line with 'Depression: the treatment and management of depression in adults' (NICE clinical guideline 90) and 'Depression in adults with a chronic physical health problem: treatment and management' (NICE clinical guideline 91). [2003]
- 1.5.8.4 For patients with heart failure, the potential risks and benefits of drug therapies for depression should be considered carefully. [2003]
- 1.5.8.5 Patients with heart failure should consult a healthcare professional before using over-the-counter therapies for depression such as St John's wort (*Hypericum perforatum*). Healthcare professionals should be aware of the potential interaction with prescribed medication, and always ask about self-medication, including the use of herbal products. [2003]

## 1.5.9 End of life

- 1.5.9.1 Issues of sudden death and living with uncertainty are pertinent to all patients with heart failure. The opportunity to discuss these issues should be available at all stages of care. [2003]
  - 1.5.9.2 The palliative needs of patients and carers should be identified, assessed and managed at the earliest opportunity. [2003]
  - 1.5.9.3 Patients with heart failure and their carers should have access to professionals with palliative care skills within the heart failure team. [2003]
-

<sup>[18]</sup> The New York Heart Association classification of heart failure.

<sup>[19]</sup> Not all ARBs are licensed for use in heart failure in combination with ACE inhibitors.

<sup>[20]</sup> This does not include mixed race. For more information see the [full guideline](#)

<sup>[21]</sup> For practical recommendations on treatment with ACE inhibitors see 'Chronic kidney disease', [NICE clinical guideline 73](#).

<sup>[22]</sup> For more information see appendix D.

<sup>[23]</sup> For practical recommendations on treatment with ARBs see 'Chronic kidney disease', [NICE clinical guideline 73](#)

<sup>[24]</sup> See 'Atrial fibrillation', [NICE clinical guideline 36](#) for recommendations on the use of digoxin in patients with atrial fibrillation.

<sup>[25]</sup> The conditions and devices that may preclude an exercise-based rehabilitation programme include: uncontrolled ventricular response to atrial fibrillation, uncontrolled hypertension, and high-energy pacing devices set to be activated at rates likely to be achieved during exercise.

<sup>[26]</sup> This is a minimum. Patients with comorbidities or co-prescribed medications will require further monitoring. Monitoring serum potassium is particularly important if a patient is taking digoxin or an aldosterone antagonist.

## 2 Notes on the scope of the guidance

NICE guidelines are developed in accordance with a [scope](#) that defines what the guideline will and will not cover.

Topics covered by the partial update are:

- Diagnosing heart failure: symptoms and signs, use of serum natriuretic peptides (BNP and NTproBNP).
- Pharmacological treatment of heart failure including: aldosterone antagonists, angiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors, beta-blockers, and hydralazine in combination with nitrate.
- Disease monitoring in chronic heart failure: serial measurement of circulating natriuretic peptide concentrations, monitoring at home.
- Cardiac rehabilitation for heart failure.

### How this guideline was developed

NICE commissioned the National Clinical Guideline Centre for Acute and Chronic Conditions to develop this guideline. The Centre established a Guideline Development Group (see appendix A), which reviewed the evidence and developed the recommendations. An independent Guideline Review Panel oversaw the development of the guideline (see appendix B).

There is more information about [how NICE clinical guidelines are developed](#) on the NICE website. A booklet, 'How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS' is [available](#).

### 3 Implementation

NICE has developed [tools](#) to help organisations implement this guidance.

## 4 Research recommendations

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future.

### 4.1 *Beta-blockers and angiotensin-converting enzyme inhibitors for heart failure with preserved left ventricular ejection fraction*

What is the effectiveness of angiotensin-converting enzyme (ACE) inhibitors and beta-blockers (given either alone or in combination) compared with placebo in patients with heart failure and preserved left ventricular ejection fraction?

#### Why this is important

At least half of people with heart failure in the community have preserved left ventricular ejection fraction. Research has focused on heart failure with left ventricular systolic dysfunction and found several agents to be beneficial (notably ACE inhibitors, beta-blockers and aldosterone antagonists). To date, studies of treatment in patients with preserved left ventricular ejection fraction have found no significant benefit. However, there is limited evidence that suggests potential benefit of both beta-blockers and ACE inhibitors in this population. The equivocal evidence base for beta-blockers and ACE inhibitors needs to be explored in greater depth to establish whether there is definite benefit or not. This is particularly important because of the extent of heart failure with preserved left ventricular ejection fraction in the general population.

### 4.2 *Home telemonitoring, natriuretic peptide-guided therapy and formal follow-up by a heart failure team*

What is the effectiveness and cost effectiveness of home telemonitoring, monitoring of serum natriuretic peptides and formal follow-up by a heart failure team for patients with heart failure due to left ventricular systolic dysfunction?

#### Why this is important

Heart failure is characterised by repeated hospitalisation. For people with left ventricular systolic dysfunction, hospitalisation can be reduced by appropriate treatment and organised nursing care. Recent studies of ways to prevent hospitalisation have focused on telemonitoring (the patient's status is assessed in the patient's own home) and the use of serum natriuretic peptide levels (to guide up-titration of drugs) compared with 'usual' care. The studies used various research methods



and differing levels of 'usual' care, which makes it difficult to compare the results. It has been suggested that, when care is delivered by an organised heart failure team under consultant supervision, additional strategies such as telemonitoring and monitoring of serum natriuretic peptides may not confer advantage. Further research is important to ascertain whether monitoring and supervision techniques afford advantage over formal, organised care by a specialist multidisciplinary heart failure team.

### ***4.3 The role of natriuretic peptides in the management and prognosis of heart failure***

What is the optimal use of natriuretic peptides in the management and prognostic stratification of patients with heart failure?

#### **Why this is important**

Heart failure is characterised by repeated hospitalisation, high mortality in the period immediately following hospitalisation and an unpredictable course in the later stages. In people with heart failure, natriuretic peptide levels have been shown to correlate with poor prognosis. Studies of the use of natriuretic peptides to guide drug titration have suggested a potential reduction in mortality in some groups, although the overall utility of this remains uncertain in the broader population with heart failure. Research is needed in three areas:

- Whether elevated natriuretic peptides despite maximum tolerated therapy could be used to predict prognosis and to guide an 'end-of-life' strategy for late-stage heart failure.
- Whether the level of natriuretic peptides at the time of discharge could be used to prioritise routine follow-up after discharge.
- Whether routine monitoring of natriuretic peptides in people with heart failure in the community might allow optimal use of community nursing resources.

### ***4.4 Aldosterone antagonists and angiotensin II receptor antagonists in heart failure***

What is the comparative effectiveness of aldosterone antagonists and angiotensin II receptor antagonists (ARBs) in symptomatic patients with heart failure due to left ventricular systolic dysfunction who are:

- on optimal therapy with a beta-blocker and an ACE inhibitor, or

- on a beta-blocker but are intolerant of ACE inhibitors?

### Why this is important

Inhibition of the renin-angiotensin-aldosterone system with an ACE inhibitor in combination with a beta-blocker is currently the cornerstone of the management of heart failure with left ventricular systolic dysfunction.

The first question is which antagonist of the renin-angiotensin-aldosterone system should be added if the patient remains symptomatic despite being on optimal therapy with a beta-blocker and an ACE inhibitor?

In trials, both aldosterone antagonists and ARBs have been used in addition to ACE inhibitors for patients with heart failure who remain symptomatic. However, there are no trials comparing the effectiveness and safety of adding aldosterone antagonists or ARBs to otherwise optimal therapy.

The second question concerns the comparative effectiveness of aldosterone antagonists and ARBs in patients (at least 10%) who are intolerant of ACE inhibitors. An ARB may be less effective than an ACE inhibitor. Aldosterone antagonists have been shown to be beneficial in patients with heart failure due to left ventricular systolic dysfunction but most were taking an ACE inhibitor. It is important to know which is the most effective method for inhibition of the renin-angiotensin-aldosterone system when ACE inhibitors are not tolerated: an aldosterone antagonist in combination with a beta-blocker or an ARB in combination with a beta-blocker.

## 4.5 *Hydralazine in combination with nitrate for heart failure with preserved left ventricular ejection fraction*

What is the comparative effectiveness of vasodilator therapy with nitrates and hydralazine in patients with heart failure and preserved left ventricular ejection fraction?

### Why this is important

More than half of people with heart failure in the community have preserved left ventricular ejection fraction. To date, studies have not shown that ARBs, ACE inhibitors or beta-blockers afford significant prognostic benefit for this population. In patients with heart failure due to left ventricular systolic dysfunction, studies have indicated that the combination of nitrate and hydralazine improves prognosis.

The pathophysiology of heart failure with preserved left ventricular ejection fraction is not clearly understood. However, hypertension is common, arterial compliance may play a major part and increased preload is a potential problem contributing to this form of heart failure. Hydralazine is an arterial vasodilator, and nitrates may reduce preload. Research is needed to investigate whether using these drugs in combination would benefit patients with heart failure and preserved left ventricular ejection fraction.

## 5 Other versions of this guideline

### 5.1 *Full guideline*

The full guideline, [Chronic heart failure](#) contains details of the methods and evidence used to develop the guideline. It is published by the National Clinical Guideline Centre for Acute and Chronic Conditions.

### 5.2 *Information for the public*

NICE has produced [information for the public](#) explaining this guideline.

We encourage NHS and voluntary sector organisations to use text from this information in their own materials about chronic heart failure.

## 6 Related NICE guidance

- Prevention of cardiovascular disease. [NICE public health guidance 25](#) (2010).
- Chest pain of recent onset. [NICE clinical guideline 95](#) (2010).
- Unstable angina and NSTEMI. [NICE clinical guideline 94](#) (2010).
- Depression in adults with a chronic physical health problem. [NICE clinical guideline 91](#) (2009).
- Depression (partial update). [NICE clinical guideline 90](#) (2009).
- Type 2 diabetes (partial update). [NICE clinical guideline 87](#) (2009).
- Medicines adherence. [NICE clinical guideline 76](#) (2009).
- Chronic kidney disease. [NICE clinical guideline 73](#) (2008).
- Lipid modification. [NICE clinical guideline 67](#) (2008).
- Identifying and supporting people most at risk of dying prematurely. [NICE public health guidance 15](#) (2008).
- Smoking cessation services. [NICE public health guidance 10](#) (2008).
- MI: secondary prevention. [NICE clinical guideline 48](#) (2007).
- Varenicline for smoking cessation. [NICE technology appraisal guidance 123](#) (2007).
- Cardiac resynchronisation therapy for the treatment of heart failure. [NICE technology appraisal guidance 120](#) (2007).
- Atrial fibrillation. [NICE clinical guideline 36](#) (2006).
- Hypertension. [NICE clinical guideline 34](#) (2006). [Replaced by [NICE clinical guideline 127](#)]
- Brief interventions and referral for smoking cessation in primary care and other settings. [NICE public health intervention guidance 1](#) (2006).
- Implantable cardioverter defibrillators for arrhythmias. [NICE technology appraisal guidance 95](#) (2006).
- Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery. [NICE interventional procedure guidance 177](#) (2006).

## 7 Updating the guideline

NICE clinical guidelines are updated so that recommendations take into account important new information. New evidence is checked 3 years after publication, and healthcare professionals and patients are asked for their views; we use this information to decide whether all or part of a guideline needs updating. If important new evidence is published at other times, we may decide to do a more rapid update of some recommendations.

## **Appendix A: The Guideline Development Group and NICE project team for the 2010 partial update**

### *Guideline Development Group*

**Jonathan Mant (Chair)**

Professor of Primary Care Research, University of Cambridge

**Abdallah Al-Mohammad (Clinical Advisor)**

Consultant Cardiologist, Sheffield Teaching Hospitals NHS Trust

**Mark Davis**

GP (specialist in heart failure), Leeds

**Paresh Dawda**

GP, Bishops Stortford, Herts

**Paul Foley (deputy for Francisco Leyva at two GDG meetings)**

Consultant Cardiologist, Great Western Hospitals NHS Trust

**Ahmet Fuat (deputy for Mark Davis at two GDG meetings)**

GP, Darlington, County Durham

**Jane Gilmour**

Specialist Nurse, Luton and Dunstable Foundation NHS Trust

**Suzanna Hardman**

Consultant Cardiologist, Whittington NHS Trust, London

**Georgina Kirwin (until July 2009)**

Research Fellow, National Clinical Guideline Centre for Acute and Chronic Conditions

**Philippe Laramee**

Health Economist, National Clinical Guideline Centre for Acute and Chronic Conditions

**Francisco Leyva**

Consultant Cardiologist; Queen Elizabeth Hospital, Birmingham

**Hugh McIntyre**

Consultant Physician Elderly Care; East Sussex Hospitals NHS Trust

**Richard Mindham**

Patient and carer member, Cardiomyopathy Association

**Nan Newberry (from December 2008)**

Project Manager, National Clinical Guideline Centre for Acute and Chronic Conditions

**Adrian Price**

Patient and carer member, Walsall Heart and Stroke Support Group

**Alison Richards**

Information Scientist, National Clinical Guideline Centre for Acute and Chronic Conditions

**Gill Ritchie (from May 2009)**

Operations Director, National Clinical Guideline Centre for Acute and Chronic Conditions

**Sharon Swain**

Senior Research Fellow, National Clinical Guideline Centre for Acute and Chronic Conditions

**Claire Turner (until December 2008)**

Project Manager, National Clinical Guideline Centre for Acute and Chronic Conditions

***NICE project team***

**Philip Alderson**

Associate Director

**Sue Latchem (until February 2010)**

Guideline Commissioning Manager

**Sarah Dunsdon (from February 2010)**

Guideline Commissioning Manager

**Laura Bruton (until May 2010)**

Guideline Coordinator



**Elaine Clydesdale (from May 2010)**

Guideline Coordinator

**Nicole Taske**

Technical Lead

**Stephanie Kinsley**

Health Economist

**Anne-Louise Clayton and Susan Burlace**

Editors

*The Guideline Development Group for the 2003 guideline (with 2003 affiliations)*

**Jonathan Mant (Lead)**

Senior Lecturer in Public Health, University of Birmingham

**Martin Cowie (Clinical adviser)**

Professor of Cardiology, National Heart and Lung Institute, Imperial College, London

**Audrey Alimo**

Nurse Consultant for Heart Failure, Central Middlesex Hospital, London

**Graham Archard**

General Practitioner, Christchurch

**Steven Barnes**

Health Services Research Fellow in Guideline Development, National Collaborating Centre for Chronic Conditions

**Stephanie Cruickshank**

Heart failure patient and carer representative; Cardiomyopathy Nurse Specialist, St George's Hospital, London

**Perry Elliott**

Senior Lecturer in Cardiology, St George's Hospital Medical School, London

**Rose Anne Kenny**

Professor of Geriatric Medicine, University of Newcastle

**Derrick Masters**

Heart failure patient and carer representative

**Jennifer Roberts**

Senior Lecturer in Health Economics, School of Health and Related Research, University of Sheffield

**Mojgan Sani**

Consultant Pharmacist, Guys' and St Thomas' Hospital Trust and Visiting Professor, School of Pharmacy and Pharmacology, University of Bath

**Hasina Shaikh**

Information Scientist, National Collaborating Centre for Chronic Conditions

**Lip-Bun Tan**

Consultant Cardiologist, Leeds General Infirmary

**Ann Taylor**

Chartered Physiotherapist, School of Biomedical Sciences, King's College London; Research Officer, Association of Chartered Physiotherapists in Cardiac Rehabilitation

**Sarah Williams**

Project Manager, National Collaborating Centre for Chronic Conditions

## Appendix B: The Guideline Review Panel for the 2010 partial update

The Guideline Review Panel is an independent panel that oversees the development of the guideline and takes responsibility for monitoring adherence to NICE guideline development processes. In particular, the panel ensures that stakeholder comments have been adequately considered and responded to. The panel includes members from the following perspectives: primary care, secondary care, lay, public health and industry.

**Peter Robb**

Consultant ENT surgeon, Epsom General Hospital

**Christine Hine**

Consultant in Public Health (Acute Commissioning), South Gloucestershire Primary Care Trust

**John Seddon**

Lay member

**Greg Rogers**

GP, Broadstairs, Kent

**Aomesh Bhatt**

Director of Regulatory and Medical Affairs, Reckitt Benckiser

### *The Guideline Review Panel for the 2003 guideline (with 2003 affiliations)*

**Bernard Higgins (Chair)**

Consultant Chest Physician, Freeman Hospital, Newcastle upon Tyne

**Robert Higgins**

Consultant in Renal and General Medicine, University Hospitals Coventry and Warwickshire

**Marcia Kelson**

Director, Patient Involvement Unit for NICE, College of Health, London

**Peter Rutherford**

Senior Lecturer in Nephrology, Medical Director, University College of Wales College of Medicine

**Helena Shovelton**

Chief Executive, British Lung Foundation

**Fiona Wise**

Acting Director of Modernisation, Bedfordshire and Hertfordshire Strategic Health Authority

**John Young**

Medical Director, Merck Sharp and Dohme

## Appendix C: The algorithms

Algorithms for the diagnosis and treatment of heart failure can be found in section 3.2 and 3.2 of the [full guideline](#).

## Appendix D: Practical notes

The practical notes are in a [separate file](#).

## About this guideline

NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.

The guideline was developed by the National Collaborating Centre for Acute and Chronic Conditions. The Collaborating Centre worked with a group of healthcare professionals (including consultants, GPs and nurses), patients and carers, and technical staff, who reviewed the evidence and drafted the recommendations. The recommendations were finalised after public consultation.

The methods and processes for developing NICE clinical guidelines are described in [The guidelines manual](#).

This guidance updates and replaces 'Chronic heart failure' (NICE clinical guideline 5 (2003)).

The recommendations from this guideline have been incorporated into a [NICE Pathway](#). We have produced [information for the public](#) explaining this guideline. Tools to help you put the guideline into practice and information about the evidence it is based on are also [available](#).

## Your responsibility

This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

## Copyright

© National Institute for Health and Clinical Excellence 2010. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational

and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

## *Accreditation*

